Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 23768867)

1.

Evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features.

Lemancewicz D, Bolkun L, Jablonska E, Kulczynska A, Bolkun-Skornicka U, Kloczko J, Dzieciol J.

Leuk Res. 2013 Sep;37(9):1089-93. doi: 10.1016/j.leukres.2013.05.014. Epub 2013 Jun 12.

PMID:
23768867
2.

Prognostic significance of ligands belonging to tumour necrosis factor superfamily in acute lymphoblastic leukaemia.

Bolkun L, Lemancewicz D, Jablonska E, Szumowska A, Bolkun-Skornicka U, Moniuszko M, Dzieciol J, Kloczko J.

Leuk Res. 2015 Mar;39(3):290-5. doi: 10.1016/j.leukres.2014.12.012. Epub 2014 Dec 27.

PMID:
25582383
3.

BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma.

Bolkun L, Lemancewicz D, Jablonska E, Kulczynska A, Bolkun-Skornicka U, Kloczko J, Dzieciol J.

Ann Hematol. 2014 Apr;93(4):635-44. doi: 10.1007/s00277-013-1924-9. Epub 2013 Oct 19.

4.

The impact of TNF superfamily molecules on overall survival in acute myeloid leukaemia: correlation with biological and clinical features.

Bolkun L, Lemancewicz D, Jablonska E, Szumowska A, Bolkun-Skornicka U, Ratajczak-Wrona W, Dzieciol J, Kloczko J.

Ann Hematol. 2015 Jan;94(1):35-43. doi: 10.1007/s00277-014-2178-x. Epub 2014 Aug 3.

5.

Evaluation of TNF superfamily molecules release by neutrophils and B leukemic cells of patients with chronic B - cell lymphocytic leukemia.

Sawicka-Powierza J, Jablonska E, Kloczko J, Piszcz J, Garley M, Ratajczk-Wrona W.

Neoplasma. 2011;58(1):45-50.

PMID:
21067265
6.

Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma.

Fragioudaki M, Tsirakis G, Pappa CA, Aristeidou I, Tsioutis C, Alegakis A, Kyriakou DS, Stathopoulos EN, Alexandrakis MG.

Leuk Res. 2012 Aug;36(8):1004-8. doi: 10.1016/j.leukres.2012.03.012. Epub 2012 Apr 10.

PMID:
22498341
7.

Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.

Kim SJ, Lee SJ, Choi IY, Park Y, Choi CW, Kim IS, Yu W, Hwang HS, Kim BS.

Eur J Haematol. 2008 Sep;81(3):177-84. doi: 10.1111/j.1600-0609.2008.01099.x. Epub 2008 May 27.

PMID:
18510703
8.
9.

Serum BAFF and APRIL might be associated with disease activity and kidney damage in patients with anti-glomerular basement membrane disease.

Xin G, Cui Z, Su Y, Xu LX, Zhao MH, Li KS.

Nephrology (Carlton). 2013 Mar;18(3):209-14. doi: 10.1111/nep.12032.

PMID:
23317407
10.

The expression of BAFF, APRIL and TWEAK is altered in eczema skin but not in the circulation of atopic and seborrheic eczema patients.

Chen Y, Lind Enoksson S, Johansson C, Karlsson MA, Lundeberg L, Nilsson G, Scheynius A, Karlsson MC.

PLoS One. 2011;6(7):e22202. doi: 10.1371/journal.pone.0022202. Epub 2011 Jul 13.

11.

High APRIL but not BAFF serum levels are associated with poor outcome in patients with follicular lymphoma.

Li YJ, Li ZM, Xia ZJ, Li S, Xia Y, Huang HQ, Huang JJ, Yi PY, Jiang WQ.

Ann Hematol. 2015 Jan;94(1):79-88. doi: 10.1007/s00277-014-2173-2. Epub 2014 Aug 22.

PMID:
25146008
12.

TNF superfamily proteins in the serum of patients with B-ALL--preliminary study.

Jabłońska E, Dakowicz L, Ratajczak-Wrona W, Garley M, Sawicka-Powierza J, Krawczuk-Rybak M.

Clin Lab. 2014;60(10):1757-64.

PMID:
25651723
13.

Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms.

George-Chandy A, Trysberg E, Eriksson K.

Arthritis Res Ther. 2008;10(4):R97. doi: 10.1186/ar2484. Epub 2008 Aug 22.

14.

Serum BAFF and APRIL levels in patients with IgG4-related disease and their clinical significance.

Kiyama K, Kawabata D, Hosono Y, Kitagori K, Yukawa N, Yoshifuji H, Omura K, Fujii T, Mimori T.

Arthritis Res Ther. 2012 Apr 24;14(2):R86. doi: 10.1186/ar3810.

15.

Increased serum levels of a proliferation-inducing ligand in patients with bullous pemphigoid.

Watanabe R, Fujimoto M, Yazawa N, Nakashima H, Asashima N, Kuwano Y, Tada Y, Maruyama N, Okochi H, Tamaki K.

J Dermatol Sci. 2007 Apr;46(1):53-60. Epub 2007 Jan 23.

PMID:
17250993
16.

BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features.

Bojarska-Junak A, Hus I, Chocholska S, Wasik-Szczepanek E, Sieklucka M, Dmoszyńska A, Roliński J.

Leuk Res. 2009 Oct;33(10):1319-27. doi: 10.1016/j.leukres.2009.03.030. Epub 2009 Apr 23.

PMID:
19395025
17.

Serum BAFF and APRIL levels in patients with PBC.

Migita K, Ilyassova B, Kovzel EF, Nersesov A, Abiru S, Maeda Y, Komori A, Ito M, Yano K, Yatsuhashi H, Shimoda S, Ishibashi H, Nakamura M.

Clin Immunol. 2010 Feb;134(2):217-25. doi: 10.1016/j.clim.2009.09.007. Epub 2009 Oct 17.

PMID:
19840904
18.

Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemia.

Ferrer G, Hodgson K, Pereira A, Juan M, Elena M, Colomer D, Roué G, Aymerich M, Baumann T, Montserrat E, Moreno C.

Leuk Lymphoma. 2011 Nov;52(11):2064-8. doi: 10.3109/10428194.2011.591008. Epub 2011 Jun 27.

PMID:
21707303
19.

Age-related changes in BAFF and APRIL profiles and upregulation of BAFF and APRIL expression in patients with primary antibody deficiency.

Jin R, Kaneko H, Suzuki H, Arai T, Teramoto T, Fukao T, Kondo N.

Int J Mol Med. 2008 Feb;21(2):233-8.

PMID:
18204790
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk